Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Interview: AstraZeneca’s Pangalos on Landmark DAPA-HF Resultsv

11 Sep 2019

AstraZeneca’s head of R&D spoke to Scrip about the outstanding results for dapagliflozin in heart failure regardless of diabetes status.

Biocon’s Malaysia Insulin Facility Hit With 12 FDA Observations

By Penelope MacRae 12 Jul 2019

The US FDA has slapped Biocon with a dozen observations over three units at its insulin manufacturing facility in Malaysia, but the Indian biotech firm says the problems can be remedied quickly and that US launch plans are on track for its insulin product glargine challenging French drug-maker Sanofi’s multi-billion-dollar Lantus.

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug

05 Jul 2019

Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds. 

Medtech Insight: 世界の医療機器・医療技術の最新情報

UK Plan To Speed Access To ‘Cutting-Edge’ Products

By Ian Schofield 03 Jul 2019

Changes are being made to the UK’s Accelerated Access Collaborative to help streamline access to ground-breaking medicines and diagnostic tools in areas like dementia, diabetes and cancer.

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform

02 Jul 2019

Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Pharma Diabetes Market Intelligence

10 Apr 2019

These reports includes 20-year forecasts of prevalent type 1 and type 2 diabetes cases segmented by age and gender, and drug-treated diabetes, segmented by treatment type.

Scrip：世界の医薬品産業ニュースサービス

ADA Meeting's Around The Corner: Five Things To Watch For

21 Jun 2018

Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.

Datamonitor Healthcare

Future market dynamics in type 2 diabetes

13 Sep 2017

With the type two diabetes market undergoing unprecedented changes its important to know how this will shape the future dynamics of this competitive market. With our coverage you're able to analyse every aspect of this market.